ArticleAdvances in biochemical engineering/biotechnology2021
When Is an In Silico Representation a Digital Twin? A Biopharmaceutical Industry Approach to the Digital Twin Concept.
Article in Advances in biochemical engineering/biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Hybrid Modeling Framework for Predictive Digital Twins of CHO Cell Culture.Computational and structural biotechnology journal · 2026Article
- The ethical aspects of human organ-on-chip models: A mapping review.Stem cell reports · 2025Review
- Digital Twins' Advancements and Applications in Healthcare, Towards Precision Medicine.Journal of personalized medicine · 2024Review
- Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation.Molecules (Basel, Switzerland) · 2023Article
- Architectural and Technological Improvements to Integrated Bioprocess Models towards Real-Time Applications.Bioengineering (Basel, Switzerland) · 2022Article
- Model-based intensification of CHO cell cultures: One-step strategy from fed-batch to perfusion.Frontiers in bioengineering and biotechnology · 2022Article
- Digital Twins: From Personalised Medicine to Precision Public Health.Journal of personalized medicine · 2021Review
- Comparing in silico flowsheet optimization strategies in biopharmaceutical downstream processes.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital twins (DTs) are expected to render process development and life-cycle management much more cost-effective and time-efficient. A DT definition, a brief retrospect on their history and expectations for their deployment in today's business environment, and a detailed financial assessment of their attractive economic benefits are provided in this chapter. The argument that restrictive guidelines set forth by regulatory agencies would hinder the adoption of DTs in the (bio)pharmaceutical industry is revisited, concluding that those companies who collaborate with the agencies to further their technical capabilities will gain significant competitive advantage. The analyzed process development examples show high methodological readiness levels but low systematic adoption of technology. Given the technical feasibilities, financial opportunities, and regulatory encouragement, concerns regarding intellectual property and data sharing, though required to be taken into account, will at best delay an industry-wide adoption of DTs. In conclusion, it is expected that a strategic investment in DTs now will gain an advantage over competition that will be difficult to overcome by late adopters.
Indexed as
Identifiers
32797270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.